Market Access Views & Analysis

Views & Analysis

Market Access

pharmaphorum podcast Episode 210 - Neal Masia

Smoothing a contract pathway through uncertainty: In convers...

Today's podcast with Entity Risk's Neal Masia includes insights on the 340B Program, PBMs, and risk-based contracts.

Market Access

The stealth market access strategy that’s quietly making man...

There is an under-the-radar market access strategy that some manufacturers have implemented, but many others remain unaware of.

Market Access

Beyond the Bill: how do we make medicines affordable without...

Two pharmaceutical giants have paused investment in the UK. More than a setback for British life sciences, it’s a warning sign for the future.

Market Access

Frontiers Health limited podcast series, Pilar Fernández Hermida

FH25: Commercialising Health Tech and Deeptech, with Pilar F...

In a new episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with commercial strategy expert Pilar Fernández Hermida.

Market Access

pharmaphorum podcast Episode 141, Alice Valder Curran

Policy in focus: Trump’s Most Favoured Nations drug pricing ...

Alice Valder Curran, a partner at Hogan Lovells, provides an update on what's happening right now with Most Favoured Nations drug pricing.

Market Access

Unlocking oncology access: What the OECD findings mean for m...

New policies are shaping the market access landscape, such as the introduction of the EU HTA for oncology medicines.

Smoothing a contract pathway through uncertainty: In convers...

The stealth market access strategy that’s quietly making man...

Beyond the Bill: how do we make medicines affordable without...

FH25: Commercialising Health Tech and Deeptech, with Pilar F...

Policy in focus: Trump’s Most Favoured Nations drug pricing ...

Unlocking oncology access: What the OECD findings mean for m...

CHMP decision levels the playing field for GSK's RSV jab

How to meet your physicians where they are online

Views & Analysis

Editor's Picks